MedWatch

Ambu downgrades due to covid-19 and logistical challenges

The medtech firm is downgrading its annual guidance as operations and the firm's logistics chain are still being affected by the pandemic.

Photo: PR / Ambu

On Thursday evening, the medtech company lowered its guidance, as the covid-19 pandemic continues to affect the number of operations being performed while also disrupting the firm's supply chain, according to an Ambu press release.

Now, Ambu expects to realize organic growth in 2021/2022 at around 17 percent compared to 17-20 percent previously forecast. It predicts that the earnings before interest an taxes will be around 10 percent, compared to 11-12 percent predicted previously.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs